一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Divarasib；Sotorasib；Adagrasib，当前状态为研究进行中，已停止招募。登记地点显示中国Gilbert、Los Angeles、San Francisco、New Haven等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Divarasib；Sotorasib；Adagrasib · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Banner Health MD Anderson AZ · Gilbert
- Los Angeles Cancer Network · Los Angeles
- UCLA Hematology / Oncology Clinic · Los Angeles
- University of California, San Francisco · San Francisco
- Yale Cancer Center · New Haven
- University of Miami · Miami
- Florida Cancer Specialists - North;725 6th Ave South (St. Petersburg) · St. Petersburg
- University of Chicago Medical Center · Chicago
- New England Cancer Specialists · Westbrook
- Dana Farber Cancer Institute · Boston
- University of Michigan · Ann Arbor
- Cancer and Hematology Centers of Western Michigan · Grand Rapids
- Minnesota Oncology Edina · Edina
- Columbia University Medical Center · New York
- Taylor Cancer Research Center · Maumee
- Oncology Associates of Oregon, P.C · Eugene
- Oregon Health & Science University · Portland
- Fox Chase Cancer Center · Philadelphia
- Allegheny Cancer Center · Pittsburgh
- Tennessee Oncology, PLLC - Chattanooga · Chattanooga
- Baptist Clinical Research Institute · Memphis
- Tennessee Oncology · Nashville
- JPS Health Network · Fort Worth
- MD Anderson Cancer Center · Houston
- Texas Oncology - Northeast Texas · Longview
- Hospital Britanico · Buenos Aires
- Centro Oncologico Korben · Ciudad Autonoma Buenos Aires
- Liverpool Hospital · Liverpool
- GenesisCare North Shore · St Leonards
- Sunshine Coast University Hospital · Birtinya
公开的入选条件
- * Unequivocal histologically or cytologically confirmed diagnosis of metastatic or locally advanced NSCLC not amenable to treatment with surgical resection or combined chemoradiation
- * Disease progression during or after treatment with at least one prior systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting
- * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- * Documentation of the presence of a KRAS G12C mutation
- * Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 10-15 (15 preferred) unstained, freshly cut, serial slides with an associated pathology report
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- * Life expectancy of \>= 12 weeks
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06497556；登记信息更新于 2026-09-16。